UPBD UPBOUND GROUP, INC. Insider Trading

Director Brown purchases 2,329 shares at $19.41; mixed track record at UPBD (2 of 5 prior buys well-timed 90d returns).

Director Jeffrey J Brown executed two separate purchases on 2026-04-28 totaling 2,329 shares for $45,205.89 at $19.41 per share, bringing holdings to 94,840 shares. The current price of $19.76 is 27.8% below the 52-week high of $27.35, though the stock has risen 9.5% over the past 30 days. Brown's same-ticker history at UPBD shows mixed timing: his 2 prior purchases on 2026-01-06 generated 12.3% 30-day returns and 3.0% 90-day returns, while his 3 earlier purchases in late 2025 and mid-2025 resulted in negative 30- and 90-day returns, with 2 of 5 total prior buys well-timed at the 90-day mark. His broader cross-ticker track record is modestly negative on buys (17 prior buys, average 30-day return -0.5%, average 90-day return -5.7%, 41.18% win rate), suggesting limited predictive value for timing. The company shows stable fundamentals with $1.2B annual revenue, +8.7% revenue growth, though a P/E of 33.49 reflects premium valuation relative to earnings.

UPBD Director Brown purchases 2,502 shares at $17.68 across 2 transactions; stock at $19.02, down -37.2% from 52-week high.

Director Jeffrey J Brown purchased 2,502 shares in two separate transactions at $17.68 on 2026-01-06, increasing his holdings to 92,972 shares. The current price of $19.02 is substantially depressed relative to the 52-week high of $30.27. However, his prior trades at UPBD present a cautionary pattern: across 3 measurable 90-day windows at this ticker (buys on 2025-10-21, 2025-07-08, and 2025-05-06), 0 of the purchases delivered positive 90-day returns, with the two most recent buys showing -26.9% and -15.5% declines respectively over 30 days. His cross-ticker buy history shows similar weakness—17 prior buys with an average 90-day return of -9.7% and a 33.33% win rate. This purchase occurs in a company with solid fundamentals (Revenue $1,164,717,000.00, P/E of 13.03, +8.2% annual growth) but adds to a record of poorly-timed accumulation in this stock.

Director Jeffrey J Brown purchases 1,951 shares at $22.27 in 2 transactions totaling $43,448.77

Jeffrey J Brown, a Director at Upbound Group, executed 2 separate purchases totaling 1,951 shares for $43,448.77 at a blended average price of $22.27, increasing his holdings from 89,014 to 90,965 shares. Across his same-ticker history at UPBD, Brown's 5 prior buys show mixed execution: only 1 of 5 prior purchases at this ticker generated positive 90-day returns, with his most recent July 2025 buys trailing -15.5% at 30 days. His cross-ticker track record shows 17 prior buys with an average 90-day return of -8.3% and a 35.29% win rate, suggesting a pattern of purchase timing that has not consistently captured upside. The current price of $22.74 is -35.0% from the 52-week high of $35.01, placing this purchase in a depressed part of the stock's recent trading range, though the company maintains modest fundamentals with $1.2B in revenue, +8.2% annual growth, and a P/E of 12.92.

Director Brown purchases 1,653 shares at $25.90 ($42.8K) at UPBD, raising stake to 89.4K shares.

Jeffrey J Brown, a Director at Upbound Group, executed 2 separate purchases totaling 1,653 shares (1.7K shares) for $42,812.70 at a blended average price of $25.90 per share on 2025-07-08, increasing his post-transaction holdings to 89,400 shares from 87,747 shares (+1.9%). The current stock price of $26.34 stands 30.3% below the 52-week high of $37.78, and the stock has gained 22.4% over 90 days despite this pullback. His prior trades at UPBD show mixed outcomes: of 5 prior purchases at this ticker, only 1 of 3 with measurable 90-day outcomes was well-timed (stock rose after purchase), while his recent April and May 2025 purchases at this ticker returned +17.7% and +3.1% respectively at the 30-day mark. His cross-ticker buy track record shows a 90-day win rate of 46.67% with an average 90-day return of -6.3%, suggesting his buy timing historically underperforms the market. This purchase occurs in a company trading at a 12.60 P/E with $1.2B in quarterly revenue and $24.8M net income, representing modest-scale acquisition of an existing substantial position rather than a major portfolio shift.

Director Brown buys 21,730 shares of UPBD at $23.75; 4th buy in 8 months despite stock down 38.8% from 52-week high.

Jeffrey J. Brown, a director at Upbound Group, purchased 21,730 shares at $23.75 on 2025-05-06, establishing his first material position in the company. This represents his fourth open-market buy at UPBD in under a year, following purchases on 2025-04-22, 2025-01-07, 2024-10-22, and 2024-07-09. The stock is currently trading at $23.14, down 38.8% from its 52-week high of $37.78, and has declined 23.5% over the past 90 days despite a modest 5.4% gain in the last 30 days. At UPBD specifically, Brown's prior buys have shown mixed 90-day timing outcomes: 2 of 4 measurable transactions posted positive 90-day returns, while 2 produced losses ranging from 0.5% to 24.3%. His cross-ticker buy history shows a 50% 90-day win rate with an average 90-day return of -3.2%, providing limited evidence of consistent timing acumen. The company trades at a P/E of 11.07 on $1.2B in latest-quarter revenue with $24.8M net income, but the repeated buying pressure from the director into a declining stock warrants attention to whether these purchases reflect conviction or execution of a mechanical schedule.

Director Jeffrey J Brown bought 1,694 shares of UPBD at $19.89; stock down -46.0% from 52-week high.

Director Jeffrey J Brown purchased 1,694 shares at $19.89 on 2025-04-22, increasing his holdings to 88,074 shares. The current price of $20.39 sits -46.0% from the 52-week high of $37.78 and down -19.6% over the past 30 days, reflecting persistent downward momentum. Brown's prior buys at UPBD show mixed timing outcomes: 3 of 5 prior purchases posted positive 90-day returns, though his most recent UPBD buy on 2025-01-07 delivered -24.3% over 90 days. The company trades at a P/E of 5.57 with $1.1B in quarterly revenue and $30.9M net income, suggesting modest fundamentals relative to valuation compression. This purchase occurs amid extended price weakness and follows a pattern of previous accumulation at this ticker, though the broader decline raises a question about whether near-term price action validates or contradicts the investment thesis underlying the prior trades.

CFO Karam Fahmi purchases 11,500 shares of UPBD at $25.82; holdings rise to 164,672 shares as stock trades -31.7% from 52-week high.

Karam Fahmi, EVP and Chief Financial Officer, purchased 11,500 shares at $25.82 on 2025-03-10, increasing his position to 164,672 shares. The transaction occurred while UPBD trades at -31.7% from its 52-week high of $37.78 and is down 23.4% over the past 90 days, suggesting the purchase happened during a period of significant price depreciation. The company's fundamentals remain stable with annual revenue growth of +8.2%, a market cap of $1,482,676,603.22, and a P/E of 7.05. The CFO's willingness to add shares during a downturn, particularly given his senior financial position, warrants examination of whether this reflects internal confidence about near-term prospects or simply routine portfolio activity.

Director Jeffrey Brown buys 1,146 shares of UPBD at $29.01; 3 of 4 prior UPBD buys were well-timed at 90-day mark (+6.4% to +22.0% returns).

Director Jeffrey Brown purchased 1,146 shares at $29.01 on 2025-01-07, bringing his holdings to 86,380 shares (+1.3% increase). This marks his sixth open-market purchase at UPBD; notably, his prior four completed buys at this ticker showed a 75% well-timed rate at the 90-day mark, with positive returns ranging from +1.7% to +22.0%, suggesting a pattern of buying into subsequent gains. The current price ($29.12) sits -22.9% below the 52-week high and -13.6% over the past 30 days, placing the stock in a depressed recent momentum context despite UPBD's underlying business showing $1,068,859,000 in quarterly revenue and positive quarterly net income of $30,860,000. However, the company posted negative full-year net income, and annual revenue declined -6.0%, adding material operational headwinds that complicate confidence signals from the purchase pattern alone.

Director BROWN JEFFREY J purchased 1,065 shares of UPBD at $29.25 on 2024-10-22; stock now down 28.3% from 52-week high.

Director Brown purchased 1,065 shares at $29.25 on 2024-10-22, increasing his holdings by 1.3% to 85,234 shares, while the stock has declined 28.3% from its 52-week high of $37.78 and fallen 12.2% in the preceding 30 days. The company fundamentals show a headwind: annual revenue contracted 6.0% year-over-year, and the company was unprofitable over its most recent full fiscal year despite generating $1.1B in quarterly revenue. Across his same-ticker history at UPBD, Brown's prior buys have shown mixed results—3 of 5 prior purchases were well-timed at the 90-day mark, with returns ranging from -4.7% to +22.0%. The current buy occurs after significant recent price weakness and amid revenue headwinds, adding a data point to monitor against the insider's historical accuracy at this ticker.

Director Brown buys 1,031 shares of UPBD at $29.82 on 2024-07-09; 3 of 4 prior UPBD buys well-timed at 90d.

Director Jeffrey J Brown purchased 1,031 shares at $29.82, increasing his holdings to 84,169 shares (+1.2%). This open-market buy occurs against a backdrop of mixed recent momentum—the stock is -3.8% over 30 days and -1.2% over 90 days, and trades -11.8% below its 52-week high of $35.21. However, Brown's same-ticker history at UPBD shows a strong pattern: 3 of 4 prior buys achieved positive 90-day returns, with notably strong outcomes on 2023-04-24 (+34.0% 30d, +43.0% 90d) and 2023-10-24 (+6.4% 30d, +22.0% 90d). This purchase represents a continuation of Brown's demonstrated tendency to accumulate UPBD shares during periods of weakness. The company reported latest-quarter revenue of $1,095,967,000.00 and a full-year net income deficit, creating a valuation context in which the insider's discretionary accumulation is noteworthy, though not yet validated by post-transaction price action.